Other highlights in the September 3 issue of JNCI

September 02, 2003

Overall U.S. Cancer Incidence, Mortality Rates Have Stabilized

Overall cancer incidence and death rates have stabilized, a trend that began in the mid- to late 1990s, according to the Annual Report to the Nation on the Status of Cancer, published in the September 3 issue of the Journal of the National Cancer Institute.

The report, produced annually by the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries, updates statistics on lung, female breast, prostate, and colorectal cancers and highlights the uses of selected surveillance data to assist in the development of state-based cancer control plans.

The authors note that observed cancer incidence rates for all cancer sites combined increased from the mid-1970s through 1992, decreased from 1992 through 1995, and were essentially stable from 1995 through 2000. Death rates for all cancer sites combined decreased beginning in 1994 and stabilized from 1998 through 2000, resulting in part from recent revisions in the coding system used on death certificates. Analysis of state data for the leading cancers revealed mixed progress in achieving national objectives outlined in Healthy People 2010, an agenda for health promotion goals created by several federal agencies.

Contact: National Cancer Institute, 301-496-6641, ncipressofficers@mail.nih.gov

Carboplatin Regimen Better Tolerated in Patients with Advanced Ovarian Cancer

The chemotherapy regimen of carboplatin plus paclitaxel is as effective as cisplatin plus paclitaxel, but the carboplatin-paclitaxel regimen is associated with better tolerability and quality of life, according to a study from the Ovarian Cancer Study Group in Germany.

Ovarian cancer is rarely cured and more than 50% of patients die within 5 years of being diagnosed with the disease. Earlier studies had suggested that carboplatin plus paclitaxel might be better tolerated than cisplatin plus paxlitaxel. To test this hypothesis, Andreas du Bois, M.D., Ph.D., of the Dr. Horst Schmidt Hospital in Wiesbaden, Germany, and colleagues performed a randomized, phase III clinical trial comparing cisplatin plus paclitaxel with carboplatin plus paclitaxel in 798 women with advanced ovarian cancer.

They found that the proportion of patients without disease progression at 2 years was not statistically significantly different between the treatment arms. They also found that, although the carboplatin-paclitaxel regimen was associated with a higher frequency of hematologic toxicities, it was associated with a lower frequency of gastrointestinal and neurologic toxicities and better quality-of-life scores than the cisplatin-paclitaxel regimen. The authors conclude that the carboplatin-paclitaxel regimen should be considered as an alternative for first-line therapy in ovarian cancer patients.

Association Found Between Blood Transfusions and HHV-8 Seropositivity

The risk of human herpesvirus 8 (HHV-8) transmission from blood transfusions is approximately equivalent to the 1-year cumulative risk of infection from non-transfusion related community sources, according to a study of children with sickle-cell disease in Uganda.

In Africa, HHV-8 prevalence is estimated to range from 20% to 80% in adults. Although HHV 8, the infectious agent associated with Kaposi's sarcoma, can be detected in peripheral blood, blood-borne transmission of the virus has not been demonstrated. To investigate a possible association between blood transfusions and HHV-8 seropositivity, Sam M. Mbulaiteye, M.D., of the National Cancer Institute, and colleagues studied 600 children with sickle-cell disease at Mulago Hospital in Kampala, Uganda.

The authors found that HHV-8 seropositivity was more frequent in children who had received transfusions than in those who never had transfusions, and that seropositivity increased with the number of reported transfusions. Overall, the estimated HHV-8 transmission risk was 2.6% per transfusion, whereas the annual risk of infection unrelated to transfusion was 2.7%.

HPV Status May Help Identify Prognosis of Cervical Lesions

Precursor lesions of the cervix persist longer, progress more rapidly, and regress more slowly in women infected with oncogenic types of human papillomavirus (HPV) compared with women infected with a non-oncogenic HPV type or in women with no HPV infection, according to a study by Nicolas F. Schlecht, Eduardo L. Franco, and colleagues at McGill University in Montreal.

Cervical cancer results from a series of reversible changes in the cervical tissue. A biomarker that could predict the duration of a cervical lesion or the speed of its progression or regression would be useful for identifying women whose lesions are likely to progress quickly to more advanced stages. Schlecht and colleagues used data from a longitudinal study of HPV infection and cervical neoplasia in Brazil and determined that the type of HPV infecting the cervical tissue may serve as such a biomarker. The authors suggest that HPV testing of women with abnormal Pap smears may help identify women who might benefit from chemopreventive treatment.
-end-
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.